

Nishida Naoshi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6755519/nishida-naoshi-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

64
papers

1,980
citations

25
h-index

43
g-index

72
ext. papers

2,482
ext. citations

6
avg, IF

5.3
L-index

| # | Paper | IF | Citations |
|----|---|------|-----------|
| 64 | Artificial intelligence (AI) models for the ultrasonographic diagnosis of liver tumors and comparison of diagnostic accuracies between AI and human experts.. <i>Journal of Gastroenterology</i> , 2022 , 57, 309 | 6.9 | 1 |
| 63 | Role of phlebotomy in the treatment of liver damage related to erythropoietic porphyria.. <i>Scientific Reports</i> , 2022 , 12, 6100 | 4.9 | 0 |
| 62 | Current Perspectives on the Immunosuppressive Niche and Role of Fibrosis in Hepatocellular Carcinoma and the Development of Antitumor Immunity. <i>Journal of Histochemistry and Cytochemistry</i> , 2021 , 221554211056853 | 3.4 | 1 |
| 61 | Accumulation of Genetic and Epigenetic Alterations in the Background Liver and Emergence of Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease. <i>Cells</i> , 2021 , 10, | 7.9 | 2 |
| 60 | Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma.. <i>Liver Cancer</i> , 2021 , 10, 583-592 | 9.1 | 0 |
| 59 | Clinicopathological analysis of hepatic immune-related adverse events in comparison with autoimmune hepatitis and graft-versus host disease. <i>Scientific Reports</i> , 2021 , 11, 9242 | 4.9 | 2 |
| 58 | Improved Tumor Response to Lenvatinib Re-Treatment after Failure of Immune Checkpoint Inhibitors in a Patient with Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021 , 10, 535-538 | 9.1 | 0 |
| 57 | Role of Oncogenic Pathways on the Cancer Immunosuppressive Microenvironment and Its Clinical Implications in Hepatocellular Carcinoma. <i>Cancers</i> , 2021 , 13, | 6.6 | 12 |
| 56 | Serum Levels of α -Fetoprotein Increased More Than 10 Years Before Detection of Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 162-170.e4 | 6.9 | 10 |
| 55 | Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma.. <i>Liver Cancer</i> , 2021 , 10, 615-628 | 9.1 | 4 |
| 54 | Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody. <i>Liver Cancer</i> , 2021 , 10, 380-393 | 9.1 | 17 |
| 53 | Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma treated with Systemic Therapies.. <i>Clinical Cancer Research</i> , 2021 , | 12.9 | 5 |
| 52 | Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1. <i>Liver Cancer</i> , 2020 , 9, 426-439 | 9.1 | 14 |
| 51 | Optimal cropping for input images used in a convolutional neural network for ultrasonic diagnosis of liver tumors. <i>Japanese Journal of Applied Physics</i> , 2020 , 59, SKKE09 | 1.4 | 2 |
| 50 | Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma. <i>Cancers</i> , 2020 , 12, | 6.6 | 13 |
| 49 | Efficacy of a modified double-guidewire technique using an uneven double lumen cannula (uneven method) in patients with surgically altered gastrointestinal anatomy (with video). <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2020 , 34, 1432-1441 | 5.2 | 8 |
| 48 | Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD-1/PD-L1 Checkpoint Blockade. <i>Cancers</i> , 2020 , 12, | 6.6 | 12 |

| | | | |
|----|--|------|----|
| 47 | Artificial Intelligence in Medical Imaging and Its Application in Sonography for the Management of Liver Tumor. <i>Frontiers in Oncology</i> , 2020 , 10, 594580 | 5.3 | 5 |
| 46 | Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B. <i>Journal of Medical Virology</i> , 2019 , 91, 1804-1810 | 19.7 | 21 |
| 45 | Current status and perspectives for computer-aided ultrasonic diagnosis of liver lesions using deep learning technology. <i>Hepatology International</i> , 2019 , 13, 416-421 | 8.8 | 12 |
| 44 | Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study. <i>Cancers</i> , 2019 , 11, | 6.6 | 92 |
| 43 | Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study. <i>Cancers</i> , 2019 , 11, | 6.6 | 71 |
| 42 | Computer aided diagnosis system developed for ultrasound diagnosis of liver lesions using deep learning 2019 , | | 3 |
| 41 | Liver damage related to immune checkpoint inhibitors. <i>Hepatology International</i> , 2019 , 13, 248-252 | 8.8 | 25 |
| 40 | Value of additional endoscopic ultrasonography for surveillance after surgical removal of intraductal papillary mucinous neoplasms. <i>Digestive Endoscopy</i> , 2018 , 30, 659-666 | 3.7 | 7 |
| 39 | Immune checkpoint blockade for the treatment of human hepatocellular carcinoma. <i>Hepatology Research</i> , 2018 , 48, 622-634 | 5.1 | 38 |
| 38 | Cystic duct antegrade stenting for cholangitis after the long-term deployment of lumen-apposing metal stents for calculous cholecystitis. <i>Endoscopic Ultrasound</i> , 2018 , 7, 349-350 | 3.6 | 1 |
| 37 | Molecular Scoring of Hepatocellular Carcinoma for Predicting Metastatic Recurrence and Requirements of Systemic Chemotherapy. <i>Cancers</i> , 2018 , 10, | 6.6 | 15 |
| 36 | Stress Response Protein RBM3 Promotes the Development of Colitis-associated Cancer. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 66-74 | 4.5 | 3 |
| 35 | Rescue EUS-guided intrahepatic biliary drainage for malignant hilar biliary stricture after failed transpapillary re-intervention. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2017 , 31, 4764-4772 | 5.2 | 26 |
| 34 | MicroRNAs for the Prediction of Early Response to Sorafenib Treatment in Human Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2017 , 6, 113-125 | 9.1 | 41 |
| 33 | Role of Immune Checkpoint Blockade in the Treatment for Human Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2017 , 35, 618-622 | 3.2 | 8 |
| 32 | Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2. <i>Digestive Diseases</i> , 2017 , 35, 589-597 | 3.2 | 27 |
| 31 | Impact of Tumor Factors on Survival in Patients with Hepatocellular Carcinoma Classified Based on Kinki Criteria Stage B2. <i>Digestive Diseases</i> , 2017 , 35, 583-588 | 3.2 | 4 |
| 30 | Contribution of C1485T mutation in the HBx gene to human and murine hepatocarcinogenesis. <i>Scientific Reports</i> , 2017 , 7, 10440 | 4.9 | 2 |

| | | | |
|----|--|------|-----|
| 29 | Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma. <i>Cancer Science</i> , 2017 , 108, 1996-2003 | 6.9 | 26 |
| 28 | Immunological Microenvironment of Hepatocellular Carcinoma and Its Clinical Implication. <i>Oncology</i> , 2017 , 92 Suppl 1, 40-49 | 3.6 | 69 |
| 27 | Oncogenic Signal and Tumor Microenvironment in Hepatocellular Carcinoma. <i>Oncology</i> , 2017 , 93 Suppl 1, 160-164 | 3.6 | 42 |
| 26 | Clinical Significance of Epigenetic Alterations in Human Hepatocellular Carcinoma and Its Association with Genetic Mutations. <i>Digestive Diseases</i> , 2016 , 34, 708-713 | 3.2 | 14 |
| 25 | Monoethanolamine Oleate Sclerotherapy for Polycystic Liver Disease. <i>Digestive Diseases</i> , 2016 , 34, 654-658 | 3.2 | 4 |
| 24 | Unique features associated with hepatic oxidative DNA damage and DNA methylation in non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 1646-53 | 3.2 | 31 |
| 23 | Validation of a Modified Substaging System (Kinki Criteria) for Patients with Intermediate-Stage Hepatocellular Carcinoma. <i>Oncology</i> , 2015 , 89 Suppl 2, 47-52 | 3.6 | 16 |
| 22 | Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2015 , 4, 253-62 | 9.1 | 130 |
| 21 | Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2015 , 33, 771-9 | 3.2 | 62 |
| 20 | Hepatic DNA Methylation Is Affected by Hepatocellular Carcinoma Risk in Patients with and without Hepatitis Virus. <i>Digestive Diseases</i> , 2015 , 33, 745-50 | 3.2 | 6 |
| 19 | Serum miR-21, miR-29a, and miR-125b Are Promising Biomarkers for the Early Detection of Colorectal Neoplasia. <i>Clinical Cancer Research</i> , 2015 , 21, 4234-42 | 12.9 | 101 |
| 18 | Impaired expression of ATP-binding cassette transporter G2 and liver damage in erythropoietic protoporphyria. <i>Hepatology</i> , 2015 , 62, 1638-9 | 11.2 | 8 |
| 17 | Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria). <i>Digestive Diseases</i> , 2015 , 33, 751-8 | 3.2 | 103 |
| 16 | Alteration of Epigenetic Profile in Human Hepatocellular Carcinoma and Its Clinical Implications. <i>Liver Cancer</i> , 2014 , 3, 417-27 | 9.1 | 33 |
| 15 | Identification of epigenetically inactivated genes in human hepatocellular carcinoma by integrative analyses of methylation profiling and pharmacological unmasking. <i>Digestive Diseases</i> , 2014 , 32, 740-6 | 3.2 | 12 |
| 14 | Genome-wide profiling of DNA methylation and tumor progression in human hepatocellular carcinoma. <i>Digestive Diseases</i> , 2014 , 32, 658-63 | 3.2 | 19 |
| 13 | Recent advancements in comprehensive genetic analyses for human hepatocellular carcinoma. <i>Oncology</i> , 2013 , 84 Suppl 1, 93-7 | 3.6 | 52 |
| 12 | Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B. <i>Journal of Medical Virology</i> , 2013 , 85, 987-95 | 19.7 | 19 |

| | | | |
|----|--|------|-----|
| 11 | Unique association between global DNA hypomethylation and chromosomal alterations in human hepatocellular carcinoma. <i>PLoS ONE</i> , 2013 , 8, e72312 | 3.7 | 27 |
| 10 | Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma. <i>Hepatology</i> , 2012 , 56, 994-1003 | 11.2 | 110 |
| 9 | Gender differences in the livers of patients with hepatocellular carcinoma and chronic hepatitis C infection. <i>Digestive Diseases</i> , 2012 , 30, 547-53 | 3.2 | 3 |
| 8 | Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review. <i>Current Genomics</i> , 2011 , 12, 130-7 | 2.6 | 148 |
| 7 | Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. <i>Hepatology</i> , 2008 , 47, 908-18 | 11.2 | 211 |
| 6 | High copy amplification of the Aurora-A gene is associated with chromosomal instability phenotype in human colorectal cancers. <i>Cancer Biology and Therapy</i> , 2007 , 6, 525-33 | 4.6 | 66 |
| 5 | Extensive methylation is associated with beta-catenin mutations in hepatocellular carcinoma: evidence for two distinct pathways of human hepatocarcinogenesis. <i>Cancer Research</i> , 2007 , 67, 4586-94 | 10.1 | 50 |
| 4 | Discrete breakpoint mapping and shortest region of overlap of chromosome arm 1q gain and 1p loss in human hepatocellular carcinoma detected by semiquantitative microsatellite analysis. <i>Genes Chromosomes and Cancer</i> , 2005 , 42, 34-43 | 5 | 23 |
| 3 | Alteration of the p14(ARF) gene and p53 status in human hepatocellular carcinomas. <i>Journal of Gastroenterology</i> , 2004 , 39, 355-61 | 6.9 | 25 |
| 2 | Prognostic impact of multiple allelic losses on metastatic recurrence in hepatocellular carcinoma after curative resection. <i>Oncology</i> , 2002 , 62, 141-8 | 3.6 | 20 |
| 1 | Comprehensive allelotyping of well-differentiated human hepatocellular carcinoma with semiquantitative determination of chromosomal gain or loss. <i>Genes Chromosomes and Cancer</i> , 2002 , 35, 329-39 | 5 | 33 |